What the Research Says
Huperzine A has been extensively studied in China, with moderate-quality clinical evidence supporting its cognitive benefits. A 2014 meta-analysis of Chinese RCTs found significant improvements in MMSE scores for Alzheimer's patients. Xu et al. (1999) demonstrated memory benefits in elderly subjects with age-related memory complaints. Its dual mechanism — AChE inhibition plus NMDA antagonism — provides a broader neuroprotective profile than single-mechanism compounds. However, most high-quality trials are from Chinese literature, and large Western multicenter trials are lacking.
